SLG
WST icon

Stanley-Laman Group’s West Pharmaceutical WST Stock Holding History

Stanley-Laman Group’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-792
Closed -$325K – 312
2022
Q1 		$325K Sell
792
-1,141
-59% -$447K 0.05% 225
2021
Q4 		$907K Hold
1,933
– – 0.11% 205
2021
Q3 		$821K Hold
1,933
– – 0.11% 201
2021
Q2 		$694K Sell
1,933
-15
-0.8% -$4.96K 0.1% 204
2021
Q1 		$549K Buy
1,948
+50
+3% +$14.3K 0.09% 206
2020
Q4 		$538K Buy
1,898
+293
+18% +$82.2K 0.1% 202
2020
Q3 		$441K Hold
1,605
– – 0.1% 185
2020
Q2 		$365K Hold
1,605
– – 0.09% 201
2020
Q1 		$244K Buy
+1,605
New +$247K 0.07% 223

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Stanley-Laman Group's WST Position: Q2 2022 in Review

Stanley-Laman Group sold out of West Pharmaceutical (WST) in Q2 2022, closing a stake of 792 shares — an estimated $325K sold.

Stanley-Laman Group first reported a position in WST in Q1 2020 and held it in 9 quarters. The position peaked at $907K in Q4 2021. 655 funds tracked by Wall St. Rank hold WST as of Q2 2022.

  • Stanley-Laman Group reported no remaining West Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Stanley-Laman Group sold 792 West Pharmaceutical shares in Q2 2022, an estimated $325K.
  • Stanley-Laman Group first reported a position in West Pharmaceutical in Q1 2020 and held it in 9 quarters.
  • Stanley-Laman Group's West Pharmaceutical position peaked at $907K in Q4 2021.
  • 655 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2022.

Based on Stanley-Laman Group's 13F filing for Q2 2022, filed 8 Aug 2022.